pharmaphorum

DECEMBER 23, 2021

The FDA has published draft guidance on how digital health technologies (DHTs) like smart and wearable devices can be used to capture data remotely from patients in clinical trials – an approach that has come to the fore since the start of the pandemic. The draft is open for comment until 22 March.

FDA 118

FDA Documentation 118

STAT

OCTOBER 20, 2023

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness.

FDA 120

FDA Documentation 120

pharmaphorum

DECEMBER 9, 2020

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.

Vaccines 111

Vaccines FDA Adverse Reactions Documentation 111

The FDA Law Blog

NOVEMBER 6, 2023

Lewis, Senior Regulatory Device & Biologics Expert — We were preparing this blogpost about FDA’s draft guidance on “Remote Interactive Evaluations” when we learned something. Compared with the COVID-centered version of the document released in April 2021, there is very little that is new or different.

FDA 105

FDA Documentation Medical Records 105

The FDA Law Blog

OCTOBER 27, 2022

Lewis, Senior Regulatory Device & Biologics Expert — FDA recently published the final guidance document “ Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA.” Brevig, Senior Regulatory Device and Biologics Exper & Richard A.

FDA 105

FDA Documentation 105

STAT

SEPTEMBER 26, 2023

As a government shutdown looms, FDA published a contingency plan stating it will immediately have to furlough 19% of its staff until it receives more funds. Food and Drug Administration will have to furlough almost one-fifth of its staff and halt work that could have a critical impact on medical-products industries , Regulatory Focus says.

FDA 105

FDA Documentation 105

Pharmaceutical Technology

FEBRUARY 8, 2023

On February 7, at a town hall organised to discuss clinical trial designs for gene therapies, FDA experts pushed pharma players to look for ways to establish clinical effectiveness despite the challenges in recruiting patients with rare diseases.

FDA 105

FDA Documentation Communication 105

The FDA Law Blog

AUGUST 16, 2023

Farquhar — Francis Godwin, Director of the Office of Manufacturing Quality of the Office of Compliance at FDA’s Center for Drug Evaluation and Research provided useful information (presentation attached here ) Tuesday at the GMP by the Sea Conference.

Documentation 97

Documentation FDA 97

The FDA Law Blog

JULY 10, 2023

After a firm submits a 510(k) to FDA, FDA will request still more information after a first-pass review. According to the 2 nd Quarter FY2023 MDUFA V Performance Report , FDA issued a request for additional information (AI request) on the first FDA review cycle for 63% to 68% of 510(k)s submitted in FY2018 to FY2022.

FDA 75

FDA Documentation Packaging Communication 75

pharmaphorum

SEPTEMBER 30, 2021

There is a lot of discussion about the power of drawing out insights from information hidden within electronic health records and insurance claims, but little regulatory guidance on how that should be undertaken. The FDA stresses it is a preliminary document and is encouraging comments, which can be filed up to 60 days after publication.

FDA 95

FDA Documentation Insurance 95

The FDA Law Blog

FEBRUARY 9, 2024

Baumhardt, Senior Medical Device Regulation Expert — As an end of the year gift, FDA finalized its guidance document, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations , in late December. c) a submission of an IDE to the FDA is not required. By Adrienne R.

FDA 105

FDA Documentation 105

The FDA Law Blog

JUNE 27, 2023

Walsh — Last fall, we blogged about the process FDA uses to review allegations of regulatory misconduct against device manufacturers, suggesting greater transparency on the FDA process was needed (see here ). FDA also requests a “detailed description of the allegation with any available supporting documentation.”

FDA 59

FDA Documentation Labelling Communication 59

The Checkup by Singlecare

DECEMBER 6, 2024

According to its prescribing information, it works to lower blood pressure by attaching to certain receptors (proteins) in the brain. In rare cases, clonidine can cause liver problems, such as hepatitis and increased liver enzymes, according to its prescribing information. Alcohols negative effects on the liver are well-documented.

Labelling 98

Labelling Documentation FDA 98

The FDA Law Blog

MARCH 7, 2024

In 2006, FDA stated that DMCs were not recommended “for most clinical studies,” particularly those in early product development, short-term studies, or studies addressing less severe outcomes. In another update, the recent draft guidance added “entities reviewing safety data” and adaptation committees.

FDA 105

FDA Documentation Adverse Reactions Communication 105

pharmaphorum

SEPTEMBER 29, 2022

Food and Drug Administration (FDA) regulation as a medical device. Determining whether a product is a medical device subject to FDA regulation necessarily begins with understanding the FDA regulatory definition of ‘medical device’. When assessing mHealth technology, the FDA will determine whether an application is either: i.

FDA 104

FDA Documentation 104

STAT

AUGUST 1, 2023

Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a manufacturing facility. Another employee failed to report all test results on product samples and, at times, printouts were tossed in the trash.

Chemotherapy 98

Chemotherapy Documentation FDA 98

The FDA Law Blog

MAY 6, 2024

Lenz, Principal Medical Device Regulation Expert — FDA recently issued a draft guidance which would update the agency’s Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions guidance. FDA provides examples of changes that are likely and unlikely to impact cybersecurity of an existing device.

FDA 105

FDA Documentation 105

The FDA Law Blog

FEBRUARY 7, 2023

Lenz, Principal Medical Device Regulation Expert — For medical device start-up companies, understanding and successfully navigating applicable FDA regulations and requirements is an important part of the path to market. There are many resources that provide information and guidance for each of these required elements.

Documentation 98

Documentation FDA Labelling 98

pharmaphorum

OCTOBER 4, 2022

On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022. Criteria for regulation.

FDA 105

FDA Documentation Labelling Communication 105

The FDA Law Blog

MAY 13, 2024

Gibbs & Ana Loloei & Véronique Li, Senior Medical Device Regulation Expert — FDA has long touted the use of real-world evidence ( RWE ). FDA recognizes the potential of RWE to support regulatory submissions of medical devices and to inform benefit-risk analysis of such products, while assuring patients have timely access to devices.

FDA 111

FDA Medical Records Documentation 111

IDStewardship

MARCH 12, 2023

Memorizing 45+ page document is certainly not a reasonable expectation, but one can certainly walk away with an awareness of general concepts and themes which are relevant. ” Labeling the use of an antibiotic as inappropriate or appropriate cannot simply be done based upon whether it is FDA-approved for a given indication.

Medication Guidelines 299

Medication Guidelines Documentation Labelling Hospitals 299

pharmaphorum

JUNE 8, 2022

Other features include compatibility with Apple’s health data sharing facility, which allows information to be shared securely with healthcare staff or carers, and the ability to export a medications list into a PDF. For example, it can warn of possible issues like mixing drugs like metronidazole or cetirizine with alcohol.

Documentation 131

Documentation Labelling FDA 131

The FDA Law Blog

DECEMBER 12, 2022

Baumhardt, Senior Medical Device Regulation Expert — With the explosion of health‑related software, many software developers are generating products with functionality that is subject to regulation by the Food and Drug Administration (FDA). Please check out FDA’s presentation on this very topic – Is My Product a Medical Device?

Documentation 23

Documentation FDA Communication 23

The Checkup by Singlecare

APRIL 24, 2025

It is approved by the Food and Drug Administration (FDA) for treating Type 2 diabetes. Mounjaro is not generally covered for weight loss since its not FDA approved for weight loss. Zepbound and Mounjaro are virtually the same drug with similar dosages but different FDA-approved uses.

Insurance 52

Insurance Customer Service Medication Guidelines Insurance Coverage 52

pharmaphorum

JANUARY 6, 2023

Sponsors running oncology and diabetes trials, for example, will ask for more information on patients’ real-life movements to demonstrate their quality of life, as well as efficacy and safety.”. Teams will develop, review, approve, and track content and documents more closely than ever, right down to version history and user access.

Documentation 111

Documentation FDA 111

The FDA Law Blog

FEBRUARY 2, 2025

Specifically, the change of ownership/location documents are quite a bit different and include some new and helpful information to assist applicants wading through the very confusing and cumbersome licensing process. The California Board of Pharmacy updated many of the application forms and guidelines in late 2024.

Packaging 59

Packaging Documentation Compounding 59

The FDA Law Blog

JANUARY 15, 2024

FDA , Petitioners, a liquid nicotine manufacturer, sued FDA arguing that the Agency was arbitrary and capricious in rejecting the Petitioner’s Premarket Tobacco Application (“PMTA”) in violation of the Administrative Procedure Act (“APA”). Youth behavioral data was not specifically required but FDA encouraged such information.

FDA 115

FDA Documentation 115

pharmaphorum

DECEMBER 30, 2022

The FDA’s interactions with Biogen in the build-up to last year’s controversial approval of Alzheimer’s disease therapy Aduhelm have been described as “inappropriate” and “atypical” in a congressional report on the review.

FDA 59

FDA Documentation Labelling 59

BioPharm

JUNE 21, 2024

The guidance document provides information about the agency’s intentions for assigning a goal date for a facility’s inspection readiness under GDUFA.

Documentation 52

Documentation FDA 52

The FDA Law Blog

SEPTEMBER 24, 2024

Livornese — FDA issued a Federal Register notice on September 13, 2024, seeking feedback on the Integrated Review format that the Center for Drug Evaluation and Research (CDER) began using as part of its New Drugs Regulatory Program (NDRP) modernization effort several years ago. By Deborah L. 89 FR 74966 at 74968 (Sept. 13, 2024).

Documentation 59

Documentation FDA Packaging 59

The FDA Law Blog

JANUARY 16, 2023

By Véronique Li, Senior Medical Device Regulation Expert — A joint eSTAR pilot (which we previewed in November) between FDA and Health Canada has now been launched. Responses from FDA and Health Canada to interested sponsors are expected within 3 business days of the email request. checks for incomplete sections.

FDA 59

FDA Documentation 59

The FDA Law Blog

FEBRUARY 21, 2024

Mullen — More than five years after FDA first announced its plan to harmonize 21 CFR Part 820 with ISO 13485, on February 2, 2024, FDA finally issued the Quality Management System Regulation (QMSR) Final Rule. FDA further retained some definitions in the QSMR. The new § 820.10 Revised § 820.3

FDA 59

FDA Labelling Packaging Documentation 59

The FDA Law Blog

OCTOBER 26, 2023

Walsh — In our June blog post , we reported on FDA’s request for comments about its program to receive information from the public alleging misconduct by other companies. FDA uses this program to help it identify risks and to determine whether further investigation is needed. 552), there are exemptions from mandatory disclosure.

FDA 52

FDA Documentation 52

The FDA Law Blog

DECEMBER 12, 2022

Shapiro — Last summer, FDA published a draft guidance, Laser-Assisted In Situ Keratomileusis (LASIK) Lasers – Patient Labeling Recommendations (July 29, 2022) setting forth a proposal for new recommended patient‑directed labeling. The approved devices already have patient‑directed labeling that FDA has approved. By Jeffrey K.

Labelling 52

Labelling FDA Documentation 52

The FDA Law Blog

FEBRUARY 22, 2023

Shapiro — More than a decade ago, FDA began systematically to incorporate review of human factors (HF) design validation within 510(k) reviews. Now FDA has issued a draft guidance , Content of Human Factors Information in Medical Device Marketing Submissions (Dec. This approach is one-size-fits-all.

FDA 64

FDA Documentation Labelling Hospitals 64

The Checkup by Singlecare

APRIL 17, 2025

Food and Drug Administration (FDA) for chronic weight management in adults with a starting, or baseline , body mass index ( BMI ) of 30 or more ( obesity ). You can contact your specific plan for more information about weight loss drug coverage , and specifically, Saxenda. It is approved by the U.S.

Insurance 52

Insurance Insurance Coverage FDA Documentation 52

The FDA Law Blog

MAY 8, 2023

Javitt — FDA recently published a long-awaited draft guidance aimed at reducing the need for prior FDA authorization of modifications to artificial intelligence/machine learning (AI/ML)-enabled device software functions (ML-DSFs). a) , and related guidance documents (e.g., See 21 CFR 807.81(a)(3) a)(3) and 21 CFR 814.39(a)

FDA 98

FDA Documentation Labelling 98